Clinical Trial

New Postoperative Intraretinal Cystoid Changes After Vitrectomy With Membrane Peeling Due to Epiretinal Membranes

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 29, 2025 (before its estimated April 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
Epiretinal membranes (ERM) are a macular disorder leading to metamorphopsia and a decrease in visual acuity. Peeling of ERM during vitrectomy is, up to date, the only possible treatment option, opening chances for improvements of visual acuity and metamorphopsia. Occurrence of new intraretinal cystoid changes was described to be associated with a lower level of visual acuity after surgery, compared to patients, that never had intraretinal cystoid changes Aim of our study was to analyze development of new intraretinal cystoid changes after vitrectomy with membrane peeling with respect to postsurgical treatment strategies.
Trial Details
NCT Number NCT06948851
Lead Sponsor Prim. Prof. Dr. Oliver Findl, MBA
Conditions Epiretinal Membrane
Enrollment 114 participants
Start Date 2024-05-16
Primary Completion 2025-04-30 (estimated)
Study Completion 2025-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-29